Prevalence of Antibodies to Epstein-Barr Virus Nuclear Antigen 2B in Persons Infected with the Human Immunodeficiency Virus

We measured the presence of antibodies to the Epstein-Barr virus (EBV) nuclear antigen 2B (EBNA2B) in patients with AIDS and related disorders, persons with human immunodeficiency virus (HIV) infection, persons at risk for HIV infection, and normal persons. Sera from 38% (16 of 43) of the patients w...

Full description

Saved in:
Bibliographic Details
Published in:The Journal of infectious diseases 1988-07, Vol.158 (1), p.186-192
Main Authors: Sculley, T. B., Cross, S. M., Borrow, P., Cooper, David A.
Format: Article
Language:English
Subjects:
Acquired Immunodeficiency Syndrome - complications
Acquired Immunodeficiency Syndrome - immunology
AIDS
AIDS/HIV
Antibodies
Antibodies, Viral - immunology
Antigens, Viral - immunology
Biological and medical sciences
Burkitt Lymphoma - complications
Burkitt Lymphoma - immunology
Cell lines
Cellulose nitrate
Epstein Barr virus infections
Epstein-Barr virus
Epstein-Barr Virus Nuclear Antigens
Herpesvirus 4, Human - immunology
HIV
Human herpesvirus 4
human immunodeficiency virus
Humans
Immunodeficiencies
Immunodeficiencies. Immunoglobulinopathies
Immunopathology
Infections
Leukocyte Count
Medical sciences
Original Articles
T lymphocytes
T-Lymphocytes - classification
Tumor Virus Infections - complications
Tumor Virus Infections - immunology
Viruses
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:We measured the presence of antibodies to the Epstein-Barr virus (EBV) nuclear antigen 2B (EBNA2B) in patients with AIDS and related disorders, persons with human immunodeficiency virus (HIV) infection, persons at risk for HIV infection, and normal persons. Sera from 38% (16 of 43) of the patients with AIDS and 35% (43 of 123) of HIV-positive individuals reacted with EBNA2B, versus 25% (21 of 83)of the high-risk patients and 7.5% (5 of 65) of the normal persons. Screening these sera against cell lines that express EBNA2B, EBNA2A, or neither antigen revealed that only a proportion of these sera contained EBNA2B-specific antibodies. Many sera reacted with both antigens. Of the EBNA2B-specific sera, 14% (6 of 43) were from patients with AIDS, 16% (20 of 123) from HIV-positive individuals, 5% (4 of 83) from high-risk individuals, and 4.5% (3 of 65) from normal persons. The presence of antibodies to the EBNA2B in HIV-infected individuals indicates that they may be infected with type B strains of EBV.
ISSN:0022-1899
1537-6613
DOI:10.1093/infdis/158.1.186